Ann: Kazia licenses paxalisib to Simcere in Greater China, page-53

Yeah that’s not the case literally thousands of western owned drugs are available in the chinese market and even companies such as Tesla service the region - you don’t carve out 10% of the market - you do exactly as we have done fine a reputable partner who knows their market.


interestingly James himself believes this deal values us for further deals at around 1B that’s pretty much x8 on the closing price of last week...

I particularly like words to this effect...

we are well funded, we are well taken care of in China, we have secured two great licensing deals in a month, we still hold the big opportunity in hand and ‘we don’t need to do anything’...

IMHO these deals has put us on the radar for licensing deals now - and we are in the enviable position of being cashed up and able to enter discussions holding all the cards and with a massive body of data flowing through potential partners will be constantly reminded of the opportunity here.